
File Date:

A.

B.

C.



IAP20 Res C + 5.1.10 08 APR 2006

In re application of:	Eaddy et al.	
Serial No.:	To Be Assigned	Group Art Unit:

Concurrently Herewith

For: Novel Compounds

Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[] Co [X] A PC are	pies of the references are enclosed: pies of the references were submitted in parent application
[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Scott Young

Registration No. 45,582

Date: Apr & ZDOG

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8160 Facsimile: (919) 483-7988

IAP20 Res'd FSTIPTO 06 APR 2006 Sheet 1 of 1

Form PTO-1449

U.S. Department of Commerce ATTY DOCKET NO. Patent and Trademark Office PR60507USW

TY DOCKET NO.

60507USW

SERIĀL NI
TO BEJĀSSI

AL'NO. 5 0 3 8

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

APPLICANT
Eaddy et al.

FILING DATE
Concurrently Herewith

U.S. PATENT DOCUMENTS

0.0.17/12/11 0000/12/17						
Examiner Initials	Document Numbe	r Date ·	Name	Class	Subclass	Filing Date If Appropriate
						_

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No
WO-01/77055-A	10 -18 -2001	wo			
WO-01/77057-A	10 -18 -2001	wo			
WO-03/016270-A	02 -27 -2003	wo			
WO-92/04310-A	03 -19 -1992	wo			
					4 1

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

SCANLAN T S ET AL.; Differential SERM Activation of the Estrogen Receptors (ERalpha and ERbeta) at AP-1 Sites; Chemistry and Biology, Current Biology; 2001; vol. 8, no. 5; 427-436; London, GB
 WILLSON T. M. ET AL.; 3-U4-(1,2-Diphenylbut-1-enyl)phenylacrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rate; Journal of Medicinal Chemistry; 25-05-1994; vol. 37, no. 11; 1550-1552; American Chemical Society; Washington, US

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and